Corevia is clinical infrastructure for healthcare brands, built by operators who ran into the limits of everything available to buy — and who think the medicine should be the point, not the overhead.
We were building and running a telehealth brand of our own. Patients, clinicians, prescriptions, refills, the whole operation. Like everyone else in that position, we went shopping first — the white-label telehealth platforms, the clinician marketplaces, the general-purpose EMRs with a video call bolted on. We ran real evaluations, not a weekend of demos.
Every one of them stopped at the same place. They will sell you clinicians. They will sell you a portal. What none of them sold was the part in between: getting a specific patient's consult to a physician actually licensed in that patient's state and credentialed for that program, keeping one clinical record instead of four systems that each hold a piece of it, and producing documentation that does not cost the clinician an evening. That orchestration was left as our problem to solve, in spreadsheets and operations headcount, forever. It is also the part that determines whether a care business is safe and whether it survives a diligence review.
So we built it, and then we found other operators standing in the same gap. The product is unusually specific as a result. It was designed against operational failures we had already lived through — the consult that sat in the wrong queue, the interaction check nobody ran because it lived in a different tab, the note written from memory at 9pm, the audit question we could not answer because the answer was in three systems. It was not designed against a feature matrix, and it shows in both directions: there are things here that competitors do not have, and things competitors advertise that we deliberately do not do.
There are corners of consumer health where it plainly isn't — where demand arrived faster than the clinical infrastructure to meet it, and what filled the gap was a checkout flow with a questionnaire attached.
You can recognize it from the outside. An intake form nobody reads. A prescription nobody meaningfully reviewed. A patient who never quite learns what they are taking, at what dose, why that dose, or what should make them stop. A refill that reorders itself. It converts well and it is a poor imitation of care, and patients in those categories are the ones who pay for the difference.
We don't think that is mostly a problem of character. It is a problem of infrastructure. When careful review is expensive and rubber-stamping is cheap, you get rubber-stamping — not because the people involved are bad, but because systems produce whatever behavior they make easiest. The corollary is the useful part: change what is easy, and you change what happens. That is a thing software can actually do.
So the platform is built so that the careful path is the default one, and the shortcut is the one that takes effort:
Complete medication list across every program and prescriber, documented allergies, prior notes, and the interaction check already run — assembled before the chart opens. A safety check that depends on someone remembering to open a second tab is not a safety check.
A decline is a first-class clinical disposition with a recorded reason, not a dead end that costs the clinician time and the business a conversion. Nothing in the workflow makes yes the cheaper answer.
Current medication, dose schedule, titration guidance and what to watch for, in the portal rather than in an email they lost. Scheduled check-ins capture how it is actually going, and a concerning answer opens a consult instead of waiting for one.
Refill requests arrive with the check-in data attached and are reviewed by a clinician. Convenient repeat dispensing without a look at how the patient is doing is the failure mode this industry is known for.
Age and identity verification happen at intake, and the depth of that check rises automatically for programs that warrant it. Verification after the prescription is theater.
Signed notes become append-only; corrections are addenda with their own author and timestamp. When a record cannot be quietly revised, the incentive to write it carefully the first time is real.
None of this is charity. Programs that monitor patients properly retain them longer, and a business that can answer an audit question in a minute is worth more than one that cannot. But the ordering matters, and we are clear about it internally: we would rather be the infrastructure that makes good medicine the default than the one that makes volume cheap. Anyone can build the second thing. It is being built right now, in several places, and patients are the ones absorbing the cost.
Our team has built and scaled products at Zoom, Blueberry Pediatrics, Simple Health, Opu Labs, Face2Face Health and Safe Health.
The engineering side of the team comes from consumer products used at scale, where latency, uptime and correctness under concurrency are not aspirations. A consult queue that double-assigns a patient under load is a clinical incident, not a bug report.
Product & platformThe other half have run virtual care businesses inside real regulatory constraints — licensure, credentialing, controlled substances, pharmacy relationships, state-by-state rules that change. They know which shortcuts look harmless and are not.
Clinical operationsThat combination is the reason clinical safety here is enforced in code rather than described in a policy document. Licensure checks, exclusive consult claims, interaction screening and the signature requirement are behaviors of the platform, not instructions in an onboarding deck.
By constructionThese are not values on a wall. Each one corresponds to something the platform does, or refuses to do, and you can check them against the product.
A control that depends on someone remembering it is not a control — it is a hope with a training slide attached. Licensure-aware routing, exclusive consult claims and required screening are enforced by the system, so the safe path is the only path available.
AI drafts. It never decides. Every clinical determination and every signature belongs to a named, licensed human who reviewed the record and can be identified afterwards. There is no configuration that lets a model approve a treatment, and there never will be.
The AI runs inside our own cloud environment under a Business Associate Agreement. No third-party model provider receives patient data, and nothing patients tell their clinician becomes training data for someone else's model.
FHIR R4 as the data model, an open API, no proprietary schema holding your records hostage. Export is a supported operation, not a negotiation. Staying with a vendor should be a choice you keep making, not a trap you discover later.
Corevia provides technology and administrative services. Care is delivered by independent, physician-owned professional practices, and no protocol on this platform overrides a clinician's decision to decline. Keeping that line clean protects patients, clinicians and the businesses built on top of us.
Including the parts that do not help us sell: where we are certified and where we are not, which capabilities are live and which are not yet, and what the platform simply does not do. Insurance billing, for one — Corevia is built for cash-pay care, and if you need claims we will tell you that in the first call rather than the fourth.
Corevia Health, LLC is a California limited liability company. It provides technology, administrative and business-support services. That is the entire scope of what it does.
Medical care is delivered exclusively by independent, physician-owned professional practices. Those practices hold the patient relationship, employ or contract the treating clinicians, and are solely responsible for clinical judgment. Corevia does not employ the treating physician, does not direct the treatment decision, and cannot override a clinician who declines to prescribe.
For HIPAA purposes, Corevia is a business associate, not a covered entity. The practices are the covered entities. We handle protected health information on their behalf under a Business Associate Agreement that defines exactly what we may do with it.
Why a buyer should care. Most states restrict the corporate practice of medicine: a non-physician company cannot own a medical practice or control clinical decisions. Platforms that blur this line create real exposure for the brands sitting on top of them — the kind that surfaces during a payment processor review, an investor diligence, a state board inquiry or a plaintiff's discovery request.
Because the separation is structural here rather than cosmetic, the questions have clean answers. Who is responsible for the clinical decision — the named licensed clinician at the professional practice. Who holds the patient record — the practice, with Corevia processing it under a BAA. Who can be shown to have signed what, and when — the audit trail, per event. You inherit a defensible structure instead of building one after the fact.
Clinicians engage with the applicable professional entity, not with Corevia Health, LLC. The same holds for the practices' patients: their relationship, and their notice of privacy practices, is with the practice.
Thirty minutes, live, on the real system — the consult queue, the routing rules, the documentation workflow and the compliance posture underneath them. Ask the hard questions while it's on screen.